The Cancer Foundation Finland has awarded us funding to continue our research into the molecular details of tumor angiogenesis.
We have just published our latest review about the role of KLK3 as an activator of VEGF-C and VEGF-D in prostate cancer. Prostate cancer is one of the most common cancers in males. It is not a question whether you will get it but only when.